首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1478948篇
  免费   96480篇
  国内免费   2004篇
耳鼻咽喉   19611篇
儿科学   49681篇
妇产科学   41577篇
基础医学   209265篇
口腔科学   37227篇
临床医学   123003篇
内科学   287396篇
皮肤病学   27566篇
神经病学   117805篇
特种医学   59816篇
外国民族医学   366篇
外科学   231474篇
综合类   29633篇
现状与发展   1篇
一般理论   315篇
预防医学   112442篇
眼科学   31975篇
药学   108870篇
  1篇
中国医学   3129篇
肿瘤学   86279篇
  2018年   34641篇
  2017年   27212篇
  2016年   31376篇
  2015年   12833篇
  2014年   17147篇
  2013年   25675篇
  2012年   41164篇
  2011年   58011篇
  2010年   40459篇
  2009年   32297篇
  2008年   56534篇
  2007年   62759篇
  2006年   39805篇
  2005年   41185篇
  2004年   41401篇
  2003年   41925篇
  2002年   39106篇
  2001年   58999篇
  2000年   60791篇
  1999年   51403篇
  1998年   14692篇
  1997年   13308篇
  1996年   13366篇
  1995年   12644篇
  1994年   12089篇
  1993年   11150篇
  1992年   41438篇
  1991年   40836篇
  1990年   40346篇
  1989年   39112篇
  1988年   36488篇
  1987年   35752篇
  1986年   34076篇
  1985年   32501篇
  1984年   24206篇
  1983年   21072篇
  1982年   12578篇
  1981年   11067篇
  1979年   22905篇
  1978年   16087篇
  1977年   13859篇
  1976年   13100篇
  1975年   14289篇
  1974年   16828篇
  1973年   16195篇
  1972年   15420篇
  1971年   14323篇
  1970年   13307篇
  1969年   12835篇
  1968年   12069篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
51.
52.
53.
54.
Delayed contrast enhancement after injection of a gadolinium-chelate (Gd-chelate) is a reference imaging method to detect myocardial tissue changes. Its localization within the thickness of the myocardial wall allows differentiating various pathological processes such as myocardial infarction (MI), inflammatory myocarditis, and cardiomyopathies. The aim of the study was first to characterize benign myocarditis using quantitative delayed-enhancement imaging and then to investigate whether the measure of the extracellular volume fraction (ECV) can be used to discriminate between MI and myocarditis.In 6 patients with acute benign myocarditis (32.2 ± 13.8 year-old, subepicardial late gadolinium enhancement [LGE]) and 18 patients with MI (52.3 ± 10.9 year-old, subendocardial/transmural LGE), myocardial T1 was determined using the Modified Look-Locker Imaging (MOLLI) sequence at 3 Tesla before and after Gd-chelate injection. T1 values were compared in LGE and normal regions of the myocardium. The myocardial T1 values were normalized to the T1 of blood, and the ECV was calculated from T1 values of myocardium and blood pre- and post-Gd injection.In both myocarditis and MI, the T1 was lower in LGE regions than in normal regions of the left ventricle. T1 of LGE areas was significantly higher in myocarditis than in MI (446.8 ± 45.8 vs 360.5 ± 66.9 ms, P = 0.003) and ECV was lower in myocarditis than in MI (34.5 ± 3.3 vs 53.8 ± 13.0 %, P = 0.004).Both inflammatory process and chronic fibrosis induce LGE (subepicardial in myocarditis and subendocardial in MI). The present study demonstrates that the determination of T1 and ECV is able to differentiate the 2 histological patterns.Further investigation will indicate whether the severity of ECV changes might help refine the predictive risk of LGE in myocarditis.  相似文献   
55.
56.
57.
The aim of the present study was to evaluate the antimicrobial activity of two synbiotic combinations, Lactobacillus fermentum with short-chain fructooligosaccharides (FOS-LF) and Bifidobacterium longum with isomaltooligosaccharides (IMO-BL), against enterohaemorrhagic Escherichia coli O157:H7 and enteropathogenic E. coli O86. Antimicrobial activity was determined (1) by co-culturing the synbiotics and pathogens in batch cultures, and (2) with the three-stage continuous culture system (gut model), inoculated with faecal slurry from an elderly donor. In the co-culture experiments, IMO-BL was significantly inhibitory to both E. coli strains, while FOS-LF was slightly inhibitory or not inhibitory. Factors other than acid production appeared to play a role in the inhibition. In the gut models, both synbiotics effectively inhibited E. coli O157 in the first vessel, but not in vessels 2 and 3. E. coli O86 was not significantly inhibited.  相似文献   
58.
59.
Farnesyltransferase (FTase) is one of the prenyltransferase family enzymes that catalyse the transfer of 15-membered isoprenoid (farnesyl) moiety to the cysteine of CAAX motif-containing proteins including Rho and Ras family of G proteins. Inhibitors of FTase act as drugs for cancer, malaria, progeria and other diseases. In the present investigation, we have developed two structure-based pharmacophore models from protein–ligand complex (3E33 and 3E37) obtained from the protein data bank. Molecular dynamics (MD) simulations were performed on the complexes, and different conformers of the same complex were generated. These conformers were undergone protein–ligand interaction fingerprint (PLIF) analysis, and the fingerprint bits have been used for structure-based pharmacophore model development. The PLIF results showed that Lys164, Tyr166, TrpB106 and TyrB361 are the major interacting residues in both the complexes. The RMSD and RMSF analyses on the MD-simulated systems showed that the absence of FPP in the complex 3E37 has significant effect in the conformational changes of the ligands. During this conformational change, some interactions between the protein and the ligands are lost, but regained after some simulations (after 2 ns). The structure-based pharmacophore models showed that the hydrophobic and acceptor contours are predominantly present in the models. The pharmacophore models were validated using reference compounds, which significantly identified as HITs with smaller RMSD values. The developed structure-based pharmacophore models are significant, and the methodology used in this study is novel from the existing methods (the original X-ray crystallographic coordination of the ligands is used for the model building). In our study, along with the original coordination of the ligand, different conformers of the same complex (protein–ligand) are used. It concluded that the developed methodology is significant for the virtual screening of novel molecules on different targets.  相似文献   
60.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号